To further explore the prognostic value of the HER2DX risk score when patients are treated with neoadjuvant and adjuvant anti-HER2-based therapy, we interrogated the CALGB-40601 publicly available breast cancer dataset,27 which include clinical data, relapse-free survival, and overall survival. This evidence concerns the gene ERBB2 and breast carcinoma.